Abstract:Background: Anaplastic thyroid carcinoma (ATC) is recognized as the most aggressive and malignant form of thyroid cancer, underscoring the critical need for effective therapeutic strategies to curb its progression and improve patient prognosis. Halofuginone (HF), a derivative of febrifugine, has displayed antitumor properties across various cancer types. However, there is a paucity of published research focused on the potential of HF to enhance the clinical efficacy of treating ATC. Objective: In this study, we thoroughly investigated the antitumor effects and mechanisms of HF in ATC, aiming to discover lead compounds for treating ATC and reveal novel therapeutic targets for ATC tumors. Methods: A series of assays, including CCK8, colony formation, tumor xenograft models, and ATC tumor organoid experiments, were conducted to evaluate the anticancer properties of HF both in vitro and in vivo. Techniques such as drug affinity responsive target stability (DARTS), western blot, immunofluorescence, and immunohistochemistry were employed to pinpoint HF target proteins within ATC. Furthermore, we harnessed the GEPIA and GEO databases and performed immunohistochemistry to validate the therapeutic potential of the glutamyl-prolyl-tRNA-synthetase (EPRS)- activating transcription factor 4 (ATF4)- type I collagen (COLI) pathway axis in the context of ATC. The study also incorporated RNA sequencing analysis, confocal imaging, and flow cytometry to delve into the molecular mechanisms of HF in ATC. Results: HF exhibited a substantial inhibitory impact on cell proliferation in vitro and on tumor growth in vivo. The DARTS results highlighted HF's influence on EPRS within ATC cells, triggering an amino acid starvation response (AASR) by suppressing EPRS expression, consequently leading to a reduction in COLI expression in ATC cells. The introduction of proline mitigated the effect of HF on ATF4 and COLI expression, indicating that the EPRS-ATF4-COLI pathway axis was a focal target of HF in ATC. Analysis of the expression levels of the EPRS, ATF4, and COLI proteins in thyroid tumors, along with an examination of the relationship between COLI expression and thyroid tumor stage, revealed that HF significantly inhibited the growth of ATC tumor organoids, demonstrating the therapeutic potential of targeting the EPRS-ATF4-COLI pathway axis in ATC. RNA sequencing analysis revealed significant differences in the pathways associated with metastasis and apoptosis between control and HF-treated cells. Transwell assays and flow cytometry experiments provided evidence of the capacity of HF to impede cell migration and induce apoptosis in ATC cells. Furthermore, HF hindered cell metastasis by suppressing the epithelial-mesenchymal transition (EMT) pathway, acting through the inhibition of FAK-AKT-NF-κB/Wnt-β-catenin signaling and restraining angiogenesis via the VEGF pathway. HF also promoted apoptosis through the mitochondrial apoptotic pathway. Conclusion: This study provided inaugural evidence suggesting that HF could emerge as a promising therapeutic agent for the treatment of ATC. The EPRS-ATF4-COLI pathway axis stood out as a prospective biomarker and therapeutic target for ATC.

The functional DIAPH3-FOXM1 interaction modulates the aggressive transformation of anaplastic thyroid carcinoma cells and Wnt/β-catenin signalling

Integrated Bioinformatics Analysis of Master Regulators in Anaplastic Thyroid Carcinoma

The Differences of Regulatory Networks Between Papillary and Anaplastic Thyroid Carcinoma: an Integrative Transcriptomics Study

HOXD9/miR-451a/PSMB8 axis is implicated in the regulation of cell proliferation and metastasis via PI3K/AKT signaling pathway in human anaplastic thyroid carcinoma

Activating transcription factor 3 mediates apoptosis and cell cycle arrest in TP53-mutated anaplastic thyroid cancer cells

IL2RA+VSIG4+ Tumor-Associated Macrophage is a Key Subpopulation of the Immunosuppressive Microenvironment in Anaplastic Thyroid Cancer.

PFKFB3 facilitates cell proliferation and migration in anaplastic thyroid carcinoma via the WNT/β‐catenin signaling pathway

SRY‑related HMG box‑2 role in anaplastic thyroid cancer aggressiveness is related to the fibronectin 1 and PI3K/AKT pathway.

Identification of Key Pathways and Genes in Anaplastic Thyroid Carcinoma Via Integrated Bioinformatics Analysis.

The transformation from thyroid papillary carcinoma to anaplastic carcinoma point of view

Bioinformatics Analysis of Key Genes and Latent Pathway Interactions Based on the Anaplastic Thyroid Carcinoma Gene Expression Profile.

The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy

MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial–mesenchymal transition in anaplastic thyroid cancer cells

GAB1 is upregulated to promote anaplastic thyroid cancer cell migration through AKT-MDR1

Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma

A Distinct Tumor Microenvironment Makes Anaplastic Thyroid Cancer More Lethal but Immunotherapy Sensitive Than Papillary Thyroid Cancer

CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment

DIAPH1 is Upregulated and Inhibits Cell Apoptosis Through ATR/p53/Caspase-3 Signaling Pathway in Laryngeal Squamous Cell Carcinoma.

Identification of novel characteristic biomarkers and immune infiltration profile for the anaplastic thyroid cancer via machine learning algorithms

Ophiopogonin D′ inhibited tumour growth and metastasis of anaplastic thyroid cancer by modulating JUN/RGS4 signalling

UHRF1 Suppression Promotes Cell Differentiation and Reduces Inflammatory Reaction in Anaplastic Thyroid Cancer